Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells

Human Gene Therapy

Volumn 10, Issue 3, 1999, Pages 375-383

  Serguera, Che ^a   Bohl, Delphine ^a   Rolland, Eric ^b   Prevost, Philippe ^b   Heard, Jean Michel ^a  

^a INSTITUT PASTEUR   (France)

^b Bioartificial Organs Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ERYTHROPOIETIN; MIFEPRISTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CELL IMMORTALIZATION; CELL STRAIN 3T3; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENCAPSULATION; GENETIC ENGINEERING; HEMATOCRIT; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERITONEAL CAVITY; SUBCUTANEOUS DRUG ADMINISTRATION;

3T3 CELLS; ANIMALS; BLOTTING, SOUTHERN; CAPSULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOCRIT; MICE; MIFEPRISTONE; RETROVIRIDAE; TIME FACTORS;

ANIMALIA; MURINAE;

EID: 0033540655     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018823     Document Type: Article

References (55)

1. AEBISCHER, P., SCHLUEP, M., DÉGLON, N., JOSEPH, J.M., HIRT, L., HEYD, B., GODDARD, M., HAMMANG, J.P., ZURN, A.D., KATO, A.C., REGLI, F., and BAETGE, E.E. (1996). Intrathecal delivery of CNTF using encapsulated genetically-modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med. 2, 696-699.
2. AL-HENDY, A., HORTELANO, G., TANNENBAUM, G.S., and CHANG, P.L. (1995). Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts an alternate approach to somatic gene therapy. Hum. Gene Ther. 6, 165-175.
3. ANAGNOSTOU, A., LEE, E.S., KESSIMIAN, N., LEVINSON, R., and STEINER, M. (1990). Erythropoietin has a mitogenic and positive chemiotactic effect on endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 87, 5978-5882.
4. BOHL, D., and HEARD, J. (1997). Modulation of erythropoietin delivery from engineered muscles in mice. Hum. Gene Ther. 8, 195-204.
5. BOHL, D., NAFFAKH, N., and HEARD, J.M. (1997). Long term control of erythropoietin secretion levels by tetracycline in mice transplanted with engineered primary myoblasts. Nature Med. 3, 299-312.
6. BOHL, D., SALVETTI, A., MOULLIER, P., and HEARD, J.M. (1998). Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92, 1512-1517.
7. CHEN, G., KOYOMA, K., YUAN, X., LEE, Y., ZHOU, Y.T., O'DOHERTY, R., NEWGARD, C.B., and UNGER, R.H. (1996). Disappearance of body fat in normal rats induced by adeno-virus-mediated leptin gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93, 14795-14799.
8. COSSET, F.L., TAKEUCHI, Y., BATTINI, J.L., WEISS, R.A., and COLLINS, M.K. (1995). High-liter packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
9. DAI, Y.F., QIU, X.F., XUE, J.L., HSUEH, J.L., and LIU, Z.D. (1992). High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patients by retroviral vectors. Sci. China B 35, 183-193.
10. DANOS, O., and MULLIGAN, R.C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85, 6460-6464.
11. DWARKI, V.J., BELLONI, P., NIJJAR, T., SMITH, J., COUTO, L., RABIER, M., CLIFT, S., BERNS, A., and COHEN, L.K. (1995). Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. U.S.A. 92, 1023-1027.
12. GOSSEN, M., FREUNDLIEB, S., BENDER, G., MÜLLER, G., HILLEN, W., and BUJARD, H. (1959). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.
13. HERZOG, R.W., HAGSTROM, J.N., KUNG, S., TAI, S.J., WILSON, J.M., FISHER, K.J., and HIGH, K.A. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 94, 5804-5809.
14. HORTELANO, G., AL-HENDY, A., OFOSU, F.A., and CHANG, P. (1996). Delivery of human factor IX in mice by encapsulated recombinant myoblasts: A novel approach towards allogeneic gene therapy of hemophilia B. Blood 87, 5095-5103.
15. HUGHES, M., VASSILAKOS, A., ANDREW, D.W., HORTELANO, G., BELMONT, J.W., and CHANG, P.L. (1994). Delivery of a secretable adenosine deaminase throughou microcapsules: A novel approach to somatic gene therapy. Hum. Gene Ther. 5, 1445-1455.
16. ISAKA, Y., BREES, D.K., IKEGAYA, K., KANEDA, Y., IMAI, E., NOBLE, N.A., and BORDER, W.A. (1996). Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 2, 418-424.
17. ISHIBASHI, S., BROWN, M.S., GOLDSTEIN, J.L., GERARD, R.D., HAMMER, R.E., and HERZ, J. (1993). Hypercholesterolemia in LDL receptor knock-out mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883-893.
18. KAWAI, S., NIEMAN, L.K., BRANDON, D.D., UDELSMAN, R., LORIAUX, D.L., and CHROUSOS, G.P. (1987). Pharmacokinetic properties of the antiglucorticoid and antiprogesterone steroid RU 486 in man. J. Pharmacol. Exp. Ther. 241, 401-406.
19. KESSLER, P.D., PODSAKOFF, G.M., CHEN, X., McQUISTON, S.A., COLOSI, P.C., MATELIS, L.A., KURTZMAN, G.J., and BYRNE, B.J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93, 14082-14087.
20. KOEBERL, D.D., ALEXANDER, I.E., HALBERT, C.L., RUSSELL, D.W., and MILLER, A.D. (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A. 94, 1426-1431.
21. KOST, T.A., THEODORAKIS, N., and HUGHES, H. (1983). The nucleotide sequence of the chick cytoplasmic β-actin gene. Nucleic Acids Res. 11, 8287-8301.
22. LACY, P.E., HEGRE, O.D., GERASIMID-VAZEOU, A., GENTILE, F.T., and DIONNE, K.E. (1991). Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 254, 1782-1784.
23. LEROY-VIARD, K., ROUYER-FESSARD, P., and BEUZARD, Y. (1991). Improvement of mouse β-thalassemia by recombinant human erythropoietin. Blood 78, 1596-1602.
24. MAGARI, S., RIVERA, V.M., LULIUCCI, J.D., GILMAN, M., and CESAROLI, F. (1997). Pharmacologic control of a humanized gene therapy system implanted into nude mice. J. Clin. Invest. 100, 2865-2872.
25. MOULLIER, P., BOHL, D., HEARD, J.M., and DANOS, O. (1993). Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically-modified skin fibroblasts. Nature Genet. 4, 154-159.
26. MUZZIN, P., EISENSMITH, R.C., COPELAND, K.C., and WOO, S.L.C. (1996). Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93, 14804-14808.
27. NAFFAKH, N., VILLEVAL, J.L., MOULLIER, P., HENRI, A., ROUYER-FESSARD, P., DANOS, O., HEARD, J.M., and BEUZARD, Y. (1995). Sustained delivery of erythropoietin in mice by autologous implants of genetically-modified skin fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92, 3194-3198.
28. NAFFAKH, N., PINSET, C., MONTARRAS, D., LI, Z., PAULIN, D., DANOS, O., and HEARD, J.M. (1996). Long-term secretion of therapeutic proteins from genetically-modified skeletal muscles. Hum. Gene Ther. 7, 11-21.
29. NISLI, G., KAVAKLI, K., AYDINOK, Y., OZTOP, S., CETINGUL, N., and BASAK, N. (1997). Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia. Acta Haematol. 98, 199-203.
30. NO, D., YAO, T., and EVANS, R.M. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93, 3346-3351.
31. OLIVIERI, N.F., FREEDMAN, M.H., PERRINE, S.P., DOVER, G.J., and SHERIDAN, B. (1992). Trial of recombinant erythropoietin: Three patients with thalassemia intermedia. Blood 80, 3258-3260.
32. PREVOST, P., FLORI, S., COLLIER, C., MUSCAT, E., and ROLLAND, E. (1995). Application of AN69 hydrogel to islet encapsulation: Evaluation in the streptozotocin-induced diabetic rat model. Transplant. Proc. 27, 3393-3395.
33. RACHMILEWITZ, E.A., GOLDFARB, A., and DOVER, G. (1988). Administration of erythropoietin to patients with β-thalassemia intermedia: A preliminary trial. Blood 78, 1145-1147.
34. RAZ, E., WATANABE, S.M., EISENBERG, R.A., PARR, T.B., LOTZ, M., KIPPS, T.J., and CARSON, D.A. (1993). Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 90, 4523-4527.
35. RENDHAL, K.G., LEFF, S.E., OTTEN, G.R., SPRATT, S.K., BOHL, D., VAN ROEY, M., DONAHUE, B.A., COHEN, L.K., MANDEL, R.J., DANOS, O., and SNYDER, R.O. (1998). Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nature Biotech. 16, 757-761.
36. RINSCH, C., RÉGULIER, E., DÉGLON, N., DALLE, B., BEUZARD, Y., and AEBISCHER, P. (1997). A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum. Gene Ther. 8, 1881-1889.
37. RIVERA, V.M., CLACKSON, T., NATESAN, S., POLLOCK, R., AMARA, J.F., KEENAN, T., MAGARI, S.R., PHILLIPS, T., COURAGE, N.L., CERASOLI, F., DENNIS, A.H., and GILMAN, M. (1996). A humanized system for pharmacologic control of gene expression. Nature Med. 2, 1028-1032.
38. SAINT-LOUIS, D., and VERMA, I.M. (1988). An alternative approach to somatic cell gene therapy. Proc. Natl. Acad. Sci. U.S.A. 85, 3150-3154.
39. SAKAGUCHI, M., KOISHIHARA, Y., TSUDA, H., FUJIMOTO, K., SHIBUYA, K., KAWAKITA, M., and TAKASTUKI, K. (1987). The expression of functional erythropoietin receptors on an interleukin-3 dependent cell line. Biochem. Biophys. Res. Commun. 146, 7.
40. SCHARP, D., SWANSON, C., OLACK, B., LATTA, P., HEGRE, O., DOHERTY, E., GENTILE, F., FLAVIN, K., ANSARA, M., and LACY, P. (1994). Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 43, 1167-1170.
41. SETOGUCHI, Y., DANEL, C., and CRYSTAL, R.J. (1994). Stimulation of erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene using an adenovirus vector. Blood 84, 2946-2953.
42. SNYDER, R.O., MIAO, C.H., PATIJN, G.A., SPRATT, S.K., DANOS, O., NAGY, D., GOWN, A.M,. WINTHER, B., MEUSE, L., COHEN, L.K., THOMPSON, A.R., and KAY, M.A. (1997a). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. 16, 270-276.
43. SNYDER, R.O., SPRATT, S.K., LAGARDE, C., BOHL, D., KASPAR, B., SLOAN, B., COHEN, L.K., and DANOS, O. (1997b). Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8, 1891-1900.
44. SOON-SHIONG, P., FELDMAN, E., NELSON, R., HEINTZ, R., YAO, Q., ZHENG, T., MERIDETH, N., SKJAK-BRAEK, G., ESPEVIK, T., SMIDSROD, O., and SA FORD, P. (1993). Long-term reversal of diabetes by the injection of immunoprotected islets. Proc. Natl. Acad. Sci. U.S.A. 90, 5843-5847.
45. SORIANO, P., FRIEDRICH, G., and LAWINGER, P. (1991). Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells. J. Virol. 65, 2314-2319.
46. SVENSSON, E.C., BLACK, H.G., DUGGER, D.L., TRIPATHY, S.K., GOLDWASSER, E., HAO, Z., CHU, L., and LEIDEN, J. (1997). Long term erythropoietin expression in rodents and nonhuman primates following intramuscular injection of a replicative defective adenoviral vector. Hum. Gene Ther. 8, 1797-1806.
47. TAN, S., and AEBISCHER, P. (1996). The problems of delivering neuroactive molecules to the CNS. Ciba Found. Symp. 196, 211-236.
48. TRIPATHY, S.K., GOLDWASSER, E., LU, M.M., BARR, E., and LEIDEN, J.M. (1994). Stable delivery of physiological levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc. Natl. Acad. Sci. U.S.A. 91, 11557-11561.
49. TRIPATHY, S., SVENSSON, E.C., BLACK, H.B., GOLDWASSER, E., MARGALITH, M., HOBART, P.M., and LEIDEN, J.M. (1996a). Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc. Natl. Acad. Sci. U.S.A. 93, 10876-10880.
50. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996b). Immune response to transgene-encoded proteins limits the ability of gene expression after injections of replication-defective adenovirus vectors. Nature Med. 2, 545-549.
51. TSUKAMOTO, K., PEARLE, S., GLICK, J.M., and RADER, D.J. (1997). Liver-directed gene transfer and prolonged expression of three major human apo E isoforms in apoE-deficient mice. J. Clin. Invest. 100, 107-114.
52. VILLEVAL, J.L., ROUYER-FESSARD, P., BLUMENFELD, N., HENRI, A., VAINCHENKER, W., and BEUZARD, Y. (1994). Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves murine beta thalassemia. Blood 84, 928-933.
53. WANG, T., LACIK, I., BRISSOVA, M., ANILKUMAR, A.V., PROKOP, A., HUNKELER, D., GREEN, R., SHAHROKHI, K., and POWERS, A.C. (1997). An encapsulation system for the immunoisolation of pancreatic islets. Nature Biotech. 15, 358-362.
54. WANG, Y., O'MALLEY, B.W., JR., TASAI, S.Y., and O'MALLEY, B.W. (1994). A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. U.S.A. 91, 8180-8184.
55. WANG, Y., DEMAYO, F.J., TSAI, S.Y., and O'MALLEY, B.W. (1997). Ligand-inducible and liver-specific target gene expression in transgenic mice. Nature Biotech. 15, 239-243.